Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomised Evaluation of Visual Function After Bilateral Implantation of Two Types of Presbyopia-correcting IOLs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03117426
Recruitment Status : Completed
First Posted : April 18, 2017
Last Update Posted : May 2, 2018
Sponsor:
Collaborator:
Abbott Medical Optics
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:

Since the introduction of intraocular lenses (IOL) in the treatment of cataract, the postoperative accommodative loss of the human eye has been a trending topic. Numerous studies show a high rate of spectacle-independency after bilateral implantation of multifocal IOLs (MIOL). However, glare, halos, and reduced visual acuity under different light conditions are common complaints after MIOL implantation. Due to its unique design, the TECNIS® Symfony Extended Range of Vision ZXR00 IOL (Abbott Medical Optics, Santa Ana, USA, hereinafter referred to as Symfony IOL) is theoretically providing a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs under different light conditions.

The goal of this study is to compare the AT LISA tri 839MP IOL (Carl Zeiss Meditec AG, Jena, Germany, hereinafter referred to as AT LISA IOL) versus the Symfony IOL in terms of postoperative achieved visual acuity at different distances, patient satisfaction (e.g. spectacle-independency, QoL), and postoperative complication profile (e.g. halo's and glare) under different light conditions. So far, there are no published studies comparing both IOLs. Therefore, we will perform this randomized control trial.


Condition or disease Intervention/treatment Phase
Cataract Presbyopia Device: SYMFONY IOL Device: AT LISA tri 839MP IOL Not Applicable

Detailed Description:

Rationale: Since the introduction of intraocular lenses (IOL) in the treatment of cataract, the postoperative accommodative loss of the human eye has been a trending topic. Numerous studies show a high rate of spectacle-independency after bilateral implantation of multifocal IOLs (MIOL). However, glare, halos, and reduced visual acuity under different light conditions are common complaints after MIOL implantation. Due to its unique design, the TECNIS® Symfony Extended Range of Vision ZXR00 IOL (Abbott Medical Optics, Santa Ana, USA, hereinafter referred to as Symfony IOL) is theoretically providing a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs under different light conditions.

The goal of this study is to compare the AT LISA tri 839MP IOL (Carl Zeiss Meditec AG, Jena, Germany, hereinafter referred to as AT LISA IOL) versus the Symfony IOL in terms of postoperative achieved visual acuity at different distances, patient satisfaction (e.g. spectacle-independency, QoL), and postoperative complication profile (e.g. halo's and glare) under different light conditions. So far, there are no published studies comparing both IOLs. Therefore, we will perform this randomized control trial.

Objective: The primary objective of this study is to compare the postoperative visual outcomes in a series of patients bilaterally implanted with the AT LISA IOL versus those bilaterally implanted with the Symfony IOL.

Study design: Single-centre randomised clinical trial. Study population: 30 patients (60 eyes) with bilateral cataract who require cataract surgery.

Intervention (if applicable): Cataract surgery with bilateral implantation of either a Symfony IOL or an AT LISA IOL.

Main study parameters/endpoints: The primary endpoint is the binocular uncorrected visual acuity at 66 cm distance under both photopic and mesopic conditions 13 weeks postoperatively. Secondary endpoints are: binocular (un)corrected visual acuity at far (4 meters) and near (40 cm) under both photopic and mesopic conditions, reading performance, patient satisfaction, and complication profile.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Both lens models used in this study are CE-marked and commercially available. The pre- and postoperatively examinations to be performed in this study are part of the regular medical treatment of patients with cataract who need cataract surgery. There is one more postoperative visit compared to standard cataract surgery. Potential risks, such as postoperative residual refractive error, halo's and glare, associated with multifocal IOL implantation are expected to be comparable or even lower after implantation of Symfony IOL. Spectacle-independency and high quality visual acuity postoperatively are the expected major benefits of implantation of the Symfony IOL.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Subject-masked Evaluation of Visual Function After Bilateral Implantation of Two Types of Presbyopia-correcting IOLs: the Symfony-study
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : September 30, 2017
Actual Study Completion Date : October 30, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: SYMFONY IOL

The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).

Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag.

Device: SYMFONY IOL
IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
Other Name: EDOF IOL

Active Comparator: AT LISA tri 839MP IOL

This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.

Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag.

Device: AT LISA tri 839MP IOL
IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
Other Name: Trifocal IOL




Primary Outcome Measures :
  1. Binocular uncorrected intermediate (66cm) visual acuity under both photopic and mesopic conditions. [ Time Frame: 3 months / 13 weeks ]
    The mean binocular uncorrected intermediate visual acuity at 66 cm under both photopic and mesopic conditions at 13 weeks (3 months) postoperatively


Secondary Outcome Measures :
  1. Binocular visual acuity [ Time Frame: 3 months / 13 weeks ]
    At 4 meter, 40 cm, including reading speed

  2. Quality of Life [ Time Frame: pre-op and 3 months/13 weeks ]
    QoL questionnaires

  3. Contrast sensitivity [ Time Frame: 3 months/13 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Minimum 21 years of age
  • Bilateral cataract
  • Bilateral implantation of Tecnis Symfony IOL or AT LISA IOL (same lens model in both eyes)
  • Expected postoperative astigmatism ≤ 1.00 D (combination with FLACS AK is tolerated up to 1.5 D preoperative astigmatism)
  • IOL power calculation between +10.00 D and 32.00 D
  • Expected postoperative best-corrected visual acuity of logMAR +0.3 or better
  • Availability to undergo second eye surgery within 2 weeks of the first eye surgery
  • Willing and able to comply with scheduled visits and other study procedures
  • Signed informed consent.

Exclusion Criteria:

  • Previous corneal surgery and/or reshaping
  • Clinically significant corneal endothelial dystrophy (e.g., Fuchs' dystrophy)
  • Irregular astigmatism
  • Keratoconus
  • History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)
  • Extensive age related macular degeneration (atrophic or exudative age-related macular degeneration or numerous soft drusen)
  • Extensive visual field loss (e.g., glaucoma, history of cerebral vascular accidents, etc.)
  • Extensive diabetic macular disease
  • History of amblyopia and/or strabismus
  • Pseudoexfoliation syndrome or other capsule or zonular abnormalities that could affect postoperative centration or tilt of the IOL
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)
  • Cognitive, cerebral or concentration disorders (e.g. dementia, Parkinson, history of CVA, etc.)
  • Suturing of incision required at time of surgery
  • Complications during surgery of the first eye.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117426


Locations
Layout table for location information
Netherlands
Maastricht University Medical Centre
Maastricht, Limburg, Netherlands, 6202 AZ
Sponsors and Collaborators
Maastricht University Medical Center
Abbott Medical Optics
Investigators
Layout table for investigator information
Principal Investigator: Rudy Nuijts, MD PhD University Eye Clinic Maastricht, Maastricht University Medical Centre

Layout table for additonal information
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT03117426     History of Changes
Other Study ID Numbers: NL56878.068.16
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: May 2, 2018
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No IPD will be shared

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Maastricht University Medical Center:
Symfony Extended Range of Vision IOL
AT LISA tri 839MP IOL
Trifocal IOL
Extended depth of focus IOLs
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Presbyopia
Lens Diseases
Eye Diseases
Refractive Errors